A cross-sectional overview of SARS-CoV-2 genome variations in Turkey
Author:
Ergünay Koray1ORCID, Kaya Mücahit2, Serdar Muhittin3ORCID, Akyön Yakut1, Yılmaz Engin4ORCID
Affiliation:
1. Department of Medical Microbiology , Faculty of Medicine, Hacettepe Üniversity , Ankara , Turkey 2. Department of Molecular Biology and Genetics , Faculty of Arts and Sciences, Ondokuz Mayıs University , Samsun , Turkey 3. Department of Medical Biochemistry , Faculty of Medicine, Acıbadem Mehmet Ali Aydınlar University , Istanbul , Turkey 4. Department of Medical Biology , Faculty of Medicine, Hacettepe University , Ankara , Turkey
Abstract
Abstract
Objectives
We assessed SARS-CoV-2 genome diversity and probable impact on epidemiology, immune response and clinical disease in Turkey.
Materials and methods
Complete genomes and partial Spike (S) sequences were accessed from the Global Initiative on Sharing Avian Influenza Data (GISAID) database. The genomes were analysed for variations and recombinations using appropriate softwares.
Results
Four hundred ten complete genomes and 206 S region sequences were included. Overall, 1,200 distinct nucleotide variations were noted. Mean variation count was 14.2 per genome and increased significantly during the course of the pandemic. The most frequent variations were identified as A23403G (D614G; 92.9,%), C14408T (P323L, 92.2%), C3037T (89.8%), C241T (83.4%) and GGG28881AAC (RG203KR, 62.6%). The A23403G mutation was the most frequent variation in the S region sequences (99%). Most genomes (98.3%) belonged in the SARS-CoV-2 haplogroup A. No evidence for recombination was identified in genomes representing sub-haplogroup branches. The variants B.1.1.7, B.1.351 and P.1 were detected, with a statistically-significant time-associated increase in B.1.1.7 prevalence.
Conclusions
We described prominent SARS-CoV-2 variations as well as comparisons with global virus diversity. Continuing a molecular surveillance in agreement with local disease epidemiology appears to be crucial, as vaccination and mitigation efforts are ongoing.
Publisher
Walter de Gruyter GmbH
Subject
Biochemistry, medical,Clinical Biochemistry,Molecular Biology,Biochemistry
Reference31 articles.
1. Zhu, N, Zhang, D, Wang, W, Li, X, Yang, B, Song, J, et al.. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020;382:727–33. https://doi.org/10.1056/nejmoa2001017. 2. Cucinotta, D, Maurizio Vanelli, M. WHO declares COVID-19 a pandemic. Acta Biomed 2020;91:157–60. https://doi.org/10.46692/9781447360377.023. 3. Gorbalenya, AE, Baker, SC, Baric, RS, de Groot, RJ, Drosten, C, Anastasia, A, et al.. The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 2020;5:536–44. https://doi.org/10.1038/s41564-020-0695-z. 4. Lu, R, Zhao, X, Li, J, Niu, P, Yang, B, Wu, H, et al.. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet 2020;395:565–74. https://doi.org/10.1016/s0140-6736(20)30251-8. 5. Wu, A, Peng, Y, Huang, B, Ding, X, Wang, X, Niu, P, et al.. Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China. Cell Host Microbe 2020;27:325–8. https://doi.org/10.1016/j.chom.2020.02.001.
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|